FDA approves two new hemophilia therapies

The Food and Drug Administration has approved Idelvion, the first hemophilia B therapy with up to 14-day dosing intervals, and Kovaltry, an unmodified, full-length factor VIII compound for the...
Source: Pediatric News - Category: Journals (General) Source Type: news